Compass Therapeutics Inc
CMPXHealthcare·Biotechnology·USA·Micro·NASD·Nov 13 • 7:17 AM ET
0.80-0.02 (-2.32%)
2026-11-13 13:26 CET
Market cap
$144.25M
Revenue, TTM
0.00 USD m
Net income, TTM
-86.36 USD m
Free cash flow, TTM
-61.94 USD m
EPS diluted, TTM
-0.46
Price
CMPX against its 20, 50 and 200-day averagesPatternshover a marker to name it
88.4% under the 52-week high of 6.88 on 3 Feb 2026. 52-week low 0.67 on 6 Nov 2026. Last 15 sessions, 33.5% high to low
Volume 0.01× normal · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Float: Under 100M; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
CMPX52-week range, 2% of the way up
0.676.88
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.
| Index | RUT |
|---|---|
| Employees | 39 |
| IPO | Apr 05, 2021 |
| Beta | 1.06 |
| ATR, 14d | 0.07 |
| Rel volume | 0.01 |
| Short float | 31.68% |
| Insider own | 28.51% |
| Inst own | 72.84% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $144.25M |
| Enterprise Value | -9.58M |
| Income | -86.36M |
| Sales | 0.00M |
| Book / share | 0.79 |
| Cash / share | 0.91 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 39 |
| IPO | Apr 05, 2021 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 1.01 |
| Price / cash | 0.88 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 6.79 |
| Current Ratio | 6.79 |
| Debt / equity | 0.06 |
| Long-term debt / equity | 0.05 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -0.46 |
|---|---|
| Earnings next year | -0.59 |
| Earnings next quarter | -0.15 |
| Earnings this year | -24.60% |
| Earnings next year | -13.66% |
| Earnings growth, 5 years | -9.00% |
| Past earnings growth | -4.18% 5.72% |
| Past sales growth | - - |
| Earnings vs last year | -1.27% |
| Sales vs last year | -100.00% |
| Earnings vs last quarter | -72.19% |
| Sales vs last quarter | - |
| Earnings | Nov 09 BMO |
| Surprise | -18.67% - |
Ownership
| Insiders own | 28.51% |
|---|---|
| Insider trades | 0.04% |
| Institutions own | 72.84% |
| Institution trades | -1.61% |
| Return on assets | -42.57% |
| Return on equity | -49.04% |
| Return on capital | -57.52% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | 2.07% |
| 50-day average | -29.48% |
| 200-day average | -72.64% |
Technical
| Shares out | 180.09M |
|---|---|
| Shares floating | 128.74M |
| Short / float | 31.68% |
| Short ratio | 10.45 |
| Short interest | 40.79M |
| 52-week high | 6.88 -88.4% |
| 52-week low | 0.67 +19.4% |
| Volatility | 7.96% 7.36% |
| Average range | 0.07 |
| Strength index | 39.42 |
| Market sensitivity | 1.06 |
| Relative volume | 0.01 |
| Avg Volume | 3.90M |
| Volume | 1,789 |
Performance
| Perf Week | 5.56% |
|---|---|
| Perf Month | -10.67% |
| Perf Quarter | -65.32% |
| Perf Half Y | -56.94% |
| Perf YTD | -85.08% |
| Perf Year | -83.21% |
| Perf 3Y | -42.79% |
| Perf 5Y | -77.44% |
| Perf 10Y | - |
| Recommendation | 1.40 |
| Target Price | 5.33 |
| Prev Close | 0.82 |
| Price | 0.80 |
| Change % | -2.32% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Sep 23, 2026 | Downgrade | Wedbush | Outperform → Neutral | $1 | +24.8% |
| Jul 01, 2026 | Resumed | Ladenburg Thalmann | Buy | $5 | +524.2% |
| Apr 28, 2026 | Downgrade | Raymond James | Outperform → Mkt Perform | ||
| Feb 13, 2026 | Initiated | Craig Hallum | Buy | $15 | +1,772.7% |
| Jan 05, 2026 | Initiated | William Blair | Outperform | ||
| Dec 03, 2025 | Initiated | Citizens JMP | Mkt Outperform | $10 | +1,148.4% |
| Dec 03, 2025 | Initiated | Cantor Fitzgerald | Overweight | ||
| Dec 03, 2025 | Initiated | Canaccord Genuity | Buy | $10 | +1,148.4% |
| Jul 01, 2025 | Resumed | Raymond James | Outperform | $9 | +1,023.6% |
| Apr 02, 2025 | Upgrade | Leerink Partners | Market Perform → Outperform | $6 | +649.1% |
Peers
Mkt capInsider trading
2 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Lerner Neil | Chief Accounting Officer | Oct 01 '26 | Buy | 0.92 | 20,000 | 18,400 | 420,000 | Oct 02 08:00 AM |
| Lerner Neil | Chief Accounting Officer | Sep 24 '26 | Buy | 1.14 | 2,500 | 2,850 | 400,000 | Sep 25 08:01 AM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| FESM | Fidelity Enhanced Small Cap Core ETF | AUM: 6.90B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| VHT | Vanguard Health Care ETF | AUM: 21.54B |
| ITOT | iShares Core S&P Total U.S. Stock Market ETF | AUM: 96.50B |
News
latest 14 of 200- Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +10.29%
- Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting (GlobeNewswire) +10.84%
- Compass Therapeutics to Participate in Upcoming November Investor Events (GlobeNewswire)
- Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 (GlobeNewswire)
- Emergent BioSolutions stock falls as CFO plans retirement (Investing.com)
- Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls (The Fly) -5.65%
- Compass Therapeutics FDA Setback Raises Concerns On Wall Street H.C. Wainwright Calls Tovecimig Filing Strategy Risky (Stocktwits)
- CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug Wedbush Sees Another 19% Downside (Stocktwits) -31.87%
- CMPX Stock Crashes To Over 2-Year Lows Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing (Stocktwits)
- Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback (GlobeNewswire)
- Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +5.29%
- Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 (GlobeNewswire)
- A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
Quarterly earnings
2026Q3 EPS -0.150 missed -0.126, from -0.080 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-09 08:30 | -0.150 | -0.126 | -0.150 | 0.00 | 0.00 | EPS +18.7% · sales - | vs 2025Q3, year-ago quarter · EPS +87.5% · sales - | 15 EPS · 12 sales | Open +5.01% vs SPY +0.91%. Close +10.29% vs SPY +2.37% |
| 2026Q2ended 2026-06-30 | 2026-08-06 08:30 | -0.130 | -0.111 | -0.135 | 0.00 | -0.60 | EPS +17.4% · sales -100.0% | vs 2025Q2, year-ago quarter · EPS -7.1% · sales - | 15 EPS · 12 sales | Open +2.12% vs SPY +0.05%. Close +5.29% vs SPY -0.16% |
| 2026Q1ended 2026-03-31 | 2026-05-05 08:30 | -0.100 | -0.098 | -0.098 | 0.00 | -0.82 | EPS +1.9% · sales -100.0% | vs 2025Q1, year-ago quarter · EPS -16.7% · sales - | 15 EPS · 11 sales | Open +0.52% vs SPY +0.52%. Close +0.52% vs SPY +0.80% |
| 2025Q4ended 2025-12-31 | 2026-03-05 08:30 | -0.090 | -0.094 | -0.085 | 0.00 | 0.00 | EPS -4.3% · sales - | vs 2024Q4, year-ago quarter · EPS -18.2% · sales - | 16 EPS · 13 sales | Open -2.81% vs SPY -0.45%. Close -2.81% vs SPY -0.56% |
| 2025Q3ended 2025-09-30 | 2025-11-05 08:30 | -0.080 | -0.139 | -0.085 | 0.00 | 0.00 | EPS -42.5% · sales - | vs 2024Q3, year-ago quarter · EPS 0.0% · sales - | 11 EPS · 8 sales | Open +0.79% vs SPY -0.04%. Close +0.79% vs SPY +0.35% |
| 2025Q2ended 2025-06-30 | 2025-08-11 08:30 | -0.140 | -0.124 | -0.144 | 0.00 | 0.00 | EPS +12.9% · sales - | vs 2024Q2, year-ago quarter · EPS +40.0% · sales -100.0% | 10 EPS · 8 sales | Open +0.74% vs SPY +0.04%. Close +23.70% vs SPY -0.20% |
| 2025Q1ended 2025-03-31 | 2025-05-08 08:30 | -0.120 | -0.110 | -0.120 | 0.00 | 0.00 | EPS +9.1% · sales - | vs 2024Q1, year-ago quarter · EPS +50.0% · sales - | 9 EPS · 7 sales | Open -4.55% vs SPY +0.73%. Close +1.14% vs SPY +0.70% |
| 2024Q4ended 2024-12-31 | 2025-02-27 08:30 | -0.110 | -0.098 | -0.109 | 0.00 | 0.00 | EPS +12.1% · sales - | vs 2023Q4, year-ago quarter · EPS 0.0% · sales - | 10 EPS · 6 sales | Open +1.01% vs SPY +0.39%. Close -1.68% vs SPY -1.60% |
| 2024Q3ended 2024-09-30 | 2024-11-12 08:30 | -0.080 | -0.113 | -0.076 | 0.00 | 0.00 | EPS -29.1% · sales - | vs 2023Q3, year-ago quarter · EPS 0.0% · sales - | 7 EPS · 5 sales | Open 0.00% vs SPY -0.01%. Close -5.79% vs SPY -0.31% |
| 2024Q2ended 2024-06-30 | 2024-08-12 08:30 | -0.100 | -0.096 | -0.095 | 0.88 | 0.00 | EPS +3.7% · sales - | vs 2023Q2, year-ago quarter · EPS +11.1% · sales - | 7 EPS · 5 sales | Open +2.75% vs SPY +0.23%. Close +3.67% vs SPY +0.05% |
| 2024Q1ended 2024-03-31 | 2024-05-13 08:30 | -0.080 | -0.113 | -0.079 | 0.00 | 0.00 | EPS -29.1% · sales - | vs 2023Q1, year-ago quarter · EPS +33.3% · sales - | 7 EPS · 5 sales | Open +6.88% vs SPY +0.33%. Close -2.50% vs SPY +0.01% |
| 2023Q4ended 2023-12-31 | 2024-03-21 08:30 | -0.110 | -0.094 | -0.105 | 0.00 | 0.00 | EPS +16.6% · sales - | vs 2022Q4, year-ago quarter · EPS +10.0% · sales - | 7 EPS · 5 sales | Open +2.83% vs SPY +0.56%. Close +5.66% vs SPY +0.33% |
| 2023Q3ended 2023-09-30 | 2023-11-09 08:30 | -0.080 | -0.107 | -0.078 | 0.00 | 0.00 | EPS -25.3% · sales - | vs 2022Q3, year-ago quarter · EPS -33.3% · sales - | 7 EPS · 5 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-03 08:30 | -0.090 | -0.081 | -0.089 | 0.00 | 0.00 | EPS +10.6% · sales - | vs 2022Q2, year-ago quarter · EPS +12.5% · sales - | 7 EPS · 5 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-04 08:30 | -0.060 | -0.106 | -0.062 | 0.00 | 0.00 | EPS -43.5% · sales - | vs 2022Q1, year-ago quarter · EPS -14.3% · sales - | 8 EPS · 5 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-15 08:30 | -0.100 | -0.111 | -0.100 | 0.00 | 0.00 | EPS -10.2% · sales - | vs 2021Q4, year-ago quarter · EPS -33.3% · sales - | 8 EPS · 5 sales | - |
Annual earnings
2025FY EPS -0.420 beat -0.431, from -0.360 a year earlier. Sales 0.00 matched 0.00, from 0.87 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -0.020 | - | - | 186.26 | - |
| 2029FYestimate | - | -0.346 | - | - | 110.27 | - |
| 2028FYestimate | - | -0.544 | - | - | 41.76 | - |
| 2027FYestimate | - | -0.595 | - | - | 4.62 | - |
| 2026FYestimate | - | -0.523 | - | - | 0.00 | - |
| 2025FY | -0.420 | -0.431 | -0.420 | 0.00 | 0.00 | - |
| 2024FY | -0.360 | -0.351 | -0.359 | 0.87 | 0.89 | - |
| 2023FY | -0.330 | -0.333 | -0.335 | 0.00 | 0.00 | - |
| 2022FY | -0.370 | -0.384 | -0.373 | 0.00 | 0.00 | - |
| 2021FY | -1.310 | -1.254 | -0.815 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 0.00, from 0.00 a year earlier. 2024Q2 operating margin -1,769%
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026Q4 E -0.15 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026Q4 | E | per share | 2026-11-10 | -0.15 | +0.1% |
| 2026Q4 | R | per share | 2026-11-10 | -0.15 | +0.1% |
| 2026FY | E | per share | 2026-11-09 | -0.52 | +5.5% |
| 2026FY | R | per share | 2026-11-09 | -0.52 | +5.5% |
| 2026Q4 | S | per share | 2026-11-09 | 0.00 | - |
| 2026Q3 | E | per share | 2026-11-04 | -0.13 | -0.2% |
| 2026Q3 | R | per share | 2026-11-04 | -0.13 | -0.2% |
| 2026FY | S | per share | 2026-10-20 | 0.00 | - |
| 2026Q3 | S | per share | 2026-08-14 | 0.00 | - |
| 2026Q2 | E | per share | 2026-07-19 | -0.11 | +0.2% |
| 2026Q2 | R | per share | 2026-07-19 | -0.11 | +0.2% |
| 2026Q2 | S | per share | 2026-07-19 | -0.60 | 0.0% |
| 2026Q1 | E | per share | 2026-04-27 | -0.10 | 0.0% |
| 2026Q1 | R | per share | 2026-04-27 | -0.10 | 0.0% |
| 2026Q1 | S | per share | 2026-03-12 | -0.82 | +9.1% |
| 2025FY | E | per share | 2026-03-05 | -0.43 | +0.4% |
| 2025Q4 | E | per share | 2026-03-05 | -0.09 | +2.0% |
| 2025FY | R | per share | 2026-03-05 | -0.43 | +0.4% |
| 2025Q4 | R | per share | 2026-03-05 | -0.09 | +2.0% |
| 2025FY | S | per share | 2026-03-05 | 0.00 | - |
| 2025Q4 | S | per share | 2026-03-05 | 0.00 | - |
| 2025Q3 | E | per share | 2025-10-29 | -0.14 | 0.0% |
| 2025Q3 | R | per share | 2025-10-29 | -0.14 | 0.0% |
| 2025Q3 | S | per share | 2025-08-11 | 0.00 | - |
| 2025Q2 | E | per share | 2025-07-22 | -0.12 | 0.0% |
| 2025Q2 | R | per share | 2025-07-22 | -0.12 | 0.0% |
| 2025Q2 | S | per share | 2025-06-30 | 0.00 | - |
| 2025Q1 | E | per share | 2025-04-25 | -0.11 | -0.4% |
| 2025Q1 | R | per share | 2025-04-25 | -0.11 | -0.4% |
| 2025Q1 | S | per share | 2025-04-18 | 0.00 | - |
| 2024FY | S | per share | 2025-02-24 | 0.89 | -1.8% |
| 2024FY | E | per share | 2025-02-21 | -0.35 | -0.3% |
| 2024Q4 | E | per share | 2025-02-21 | -0.10 | -0.9% |
| 2024FY | R | per share | 2025-02-21 | -0.35 | -0.3% |
| 2024Q4 | R | per share | 2025-02-21 | -0.10 | -0.9% |
| 2024Q4 | S | per share | 2025-02-18 | 0.00 | - |
| 2024Q3 | E | per share | 2024-10-30 | -0.11 | 0.0% |
| 2024Q3 | R | per share | 2024-10-30 | -0.11 | 0.0% |
| 2024Q3 | S | per share | 2024-08-12 | 0.00 | - |
| 2024Q2 | E | per share | 2024-08-11 | -0.10 | 0.0% |
| 2024Q2 | R | per share | 2024-08-11 | -0.10 | 0.0% |
| 2024Q2 | S | per share | 2024-05-13 | 0.00 | - |
| 2024Q1 | E | per share | 2024-03-26 | -0.11 | +1.1% |
| 2024Q1 | R | per share | 2024-03-26 | -0.11 | +1.1% |
| 2024Q1 | S | per share | 2024-03-21 | 0.00 | - |
| 2023FY | E | per share | 2024-01-27 | -0.33 | 0.0% |
| 2023FY | R | per share | 2024-01-27 | -0.33 | 0.0% |
| 2023FY | S | per share | 2023-11-13 | 0.00 | - |
Estimate history
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.735 | -0.01 | -0.566 | -0.815 | -0.373 | -0.335 | -0.359 | -0.422 | -0.4634 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | - |
| Shares million shares | 52 | 5 | 52 | 101 | 126 | 128 | 138 | 178 | - | 180 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.076 | -0.109 | -0.12 | -0.144 | -0.085 | -0.085 | -0.098 | -0.135 | -0.146 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 138 | 138 | 138 | 138 | 178 | 178 | 180 | 180 | 180 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY3/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00-100.0% | 0.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 1.50 | 1.47-16.0% | 1.75-7.4% | 1.89-0.5% | 1.90+17.3% | 1.62-32.5% | 2.40 | 0.00 | 2.12 |
| Gross Profit | -1.50 | -1.47 | -0.90 | -1.89 | -1.90 | -1.62 | -2.40 | 0.00 | -2.12 |
| Selling, General and Administrative Excl. Other | 92.57 | 71.37+28.1% | 55.72+15.0% | 48.47+21.9% | 39.75+34.1% | 29.64+16.6% | 25.41+84600.0% | 0.03 | 31.93 |
| Research and Development | 68.60 | 55.69+33.4% | 41.75+11.6% | 37.42+28.1% | 29.21+47.7% | 19.77+32.7% | 14.90 | - | 22.45 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -94.07 | -72.84 | -56.62 | -50.36 | -41.66 | -31.26 | -27.81 | -0.03 | -34.05 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.37-59.3% | 0.91+9000.0% | 0.01 | 1.23 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 50.62+8939.3% | 0.56 | - | 0.10 |
| Net Income Before Taxes | -86.36 | -66.49 | -49.38 | -42.49 | -39.23 | -82.18 | -29.47 | -0.04 | -34.65 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.03 | 0.00 | 0.09 |
| Consolidated Net Income | -86.36 | -66.49 | -49.38 | -42.49 | -39.23 | -82.18 | -29.50 | -0.04 | -34.74 |
| Net Income From Continuing Operations | -86.36 | -66.49 | -49.38 | -42.49 | -39.23 | -82.18 | -29.50 | -0.04 | -34.74 |
| Net Income | -86.36 | -66.49 | -49.38 | -42.49 | -39.23 | -82.18 | -29.50 | -0.04 | -34.74 |
| EPS (Recurring) per share | -0.46 | -0.42 | -0.36 | -0.33 | -0.37 | -0.46 | -0.56 | -0.01 | -0.67 |
| EPS (Basic, Before Extraordinaries) per share | -0.46 | -0.42 | -0.36 | -0.33 | -0.37 | -0.81 | -0.57 | -0.01 | -0.67 |
| EPS (Diluted) per share | -0.46 | -0.42 | -0.36 | -0.33 | -0.37 | -0.81 | -0.57 | -0.01 | -0.67 |
| EBITDA | -92.57 | -71.37 | -54.87 | -48.47 | -39.75 | -29.64 | -25.41 | -0.03 | -31.93 |
| Non-Operating Income (Expense) | 7.71 | 6.35-12.4% | 7.25-7.9% | 7.87+223.9% | 2.43+3371.4% | 0.07 | -0.19 | 0.00 | 0.73 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 15.73 | 8.37-2.2% | 8.56+39.9% | 6.12+14.8% | 5.33+32.3% | 4.03+37.5% | 2.93 | - | 0.67 |
| Price To Sales Ratio ratio | - | - | 234.36 | - | - | - | - | - | - |
| Gross Margin % | - | - | -106.24 | - | - | - | - | - | - |
| Operating Margin % | - | - | -6,661.76 | - | - | - | - | - | - |
| Net Margin % | - | - | -5,808.82 | - | - | - | - | - | - |
| Shares Outstanding million shares | 180.09 | 178.32+29.4% | 137.82+8.0% | 127.67+1.1% | 126.30+25.3% | 100.83+93.5% | 52.11+942.2% | 5.00 | 52.11 |
| Market Capitalization | 147.67 | 147.67-26.0% | 199.50+0.3% | 198.88-68.7% | 634.74+104.3% | 310.76+5.7% | 294.09 | - | - |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.39+5.4% | 0.38+2.7% | 0.37+2.8% | 0.37+2.8% | 0.37-21.3% | 0.37-21.3% | 0.36-21.7% | 0.36-23.4% |
| Gross Profit | -0.39 | -0.38 | -0.37 | -0.37 | -0.37 | -0.37-197.4% | -0.36 | -0.36 |
| Selling, General and Administrative Excl. Other | 28.41+83.9% | 26.60+28.5% | 19.93+13.2% | 17.62+8.7% | 15.45+31.3% | 20.70+34.2% | 17.60+43.0% | 16.21+8.6% |
| Research and Development | 22.01+71.8% | 19.55+19.8% | 13.38+3.6% | 13.66+6.0% | 12.81+51.2% | 16.32+48.1% | 12.91+37.8% | 12.89+5.1% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -28.80 | -26.98 | -20.30 | -17.99 | -15.82 | -21.07 | -17.97 | -16.57 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -27.17 | -25.15 | -18.32 | -15.72 | -14.26 | -19.88 | -16.63 | -15.03 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -27.17 | -25.15 | -18.32 | -15.72 | -14.26 | -19.88 | -16.63 | -15.03 |
| Net Income From Continuing Operations | -27.17 | -25.15 | -18.32 | -15.72 | -14.26 | -19.88 | -16.63 | -15.03 |
| Net Income | -27.17 | -25.15 | -18.32 | -15.72 | -14.26 | -19.88 | -16.63 | -15.03 |
| EPS (Recurring) per share | -0.15 | -0.13 | -0.10 | -0.09 | -0.08 | -0.14 | -0.12 | -0.11 |
| EPS (Basic, Before Extraordinaries) per share | -0.15 | -0.13 | -0.10 | -0.09 | -0.08 | -0.14 | -0.12 | -0.11 |
| EPS (Diluted) per share | -0.15 | -0.13 | -0.10 | -0.09 | -0.08 | -0.14 | -0.12 | -0.11 |
| EBITDA | -28.41 | -26.60 | -19.93 | -17.62 | -15.45 | -20.70 | -17.60 | -16.21 |
| Non-Operating Income (Expense) | 1.63+4.5% | 1.82+52.9% | 1.98+48.9% | 2.27+47.4% | 1.56-11.4% | 1.19-39.6% | 1.33-32.8% | 1.54-22.2% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 4.01+223.4% | 4.82+72.8% | 5.07+102.0% | 1.82-18.8% | 1.24-43.6% | 2.79+31.6% | 2.51+25.5% | 2.24+40.0% |
| Price To Sales Ratio ratio | - | - | - | - | - | - | 309.00 | 235.10 |
| Shares Outstanding million shares | 180.09+1.4% | 180.09+30.2% | 180.09+30.2% | 178.32+29.4% | 177.57+29.1% | 138.28+0.5% | 138.28+0.5% | 137.82+8.0% |
| Market Capitalization | 147.67-75.4% | 394.39+9.7% | 952.67+262.6% | 955.12+378.8% | 600.50+137.2% | 359.54+161.3% | 262.74-3.6% | 199.50+0.3% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY3/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 208.91+64.9% | 126.72-16.9% | 152.46-18.3% | 186.61+29.1% | 144.51+206.9% | 47.08 | 0.00-100.0% | 25.30-56.0% | 57.51 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.91-84.9% | 6.03+324.6% | 1.42-82.6% | 8.18+215.8% | 2.59-17.3% | 3.13 | 0.00-100.0% | 0.94-31.4% | 1.37 |
| Total Current Assets | 209.82+58.1% | 132.75-13.7% | 153.88-21.0% | 194.79+32.4% | 147.10+193.0% | 50.20 | 0.00-100.0% | 26.24-55.4% | 58.88 |
| Net Property, Plant & Equipment | 9.20+29.9% | 7.08+165.2% | 2.67-41.1% | 4.53-28.4% | 6.33+460.2% | 1.13 | 0.00-100.0% | 3.75-30.2% | 5.37 |
| Total Investments and Advances | 0.57 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.26 | 0.00-100.0% | 0.260.0% | 0.26 |
| Intangible Assets | 0.00 | - | - | - | - | - | 0.00 | - | - |
| Deferred Tax Assets | 2.56 | - | - | - | - | - | - | - | - |
| Other Assets | 0.00-100.0% | 0.57+78.1% | 0.320.0% | 0.320.0% | 0.320.0% | 0.32 | 0.00-100.0% | 0.13+8.3% | 0.12 |
| Total Assets | 222.15+58.2% | 140.40-10.5% | 156.88-21.4% | 199.65+29.8% | 153.76+196.2% | 51.91 | 0.00-100.0% | 30.38-53.0% | 64.62 |
| Short Term Debt Incl. Current Port. of LT Debt | 1.00+194.1% | 0.34-71.7% | 1.20+9.1% | 1.10+11.1% | 0.99-86.7% | 7.47+7370.0% | 0.10-97.3% | 5.58+51.2% | 3.69 |
| Accounts Payable | 1.58-29.8% | 2.25-45.0% | 4.09+21.0% | 3.38+288.5% | 0.87-17.9% | 1.06 | 0.00-100.0% | 0.63-63.6% | 1.73 |
| Other Current Liabilities | 11.38+80.9% | 6.29+150.6% | 2.51-78.5% | 11.69+33.1% | 8.78+459.2% | 1.57+15600.0% | 0.01-99.7% | 3.62+18.7% | 3.05 |
| Total Current Liabilities | 13.97+57.5% | 8.87+13.7% | 7.80-51.8% | 16.17+52.1% | 10.63+5.2% | 10.10+9081.8% | 0.11-98.7% | 9.82+16.1% | 8.46 |
| Long Term Debt | 8.83+40.2% | 6.30+1066.7% | 0.54-70.7% | 1.84-39.7% | 3.05+63.1% | 1.87 | 0.00-100.0% | 139.16-1.3% | 140.93 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 2.56 | - | - | - | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 25.36+67.2% | 15.17+81.9% | 8.34-53.7% | 18.01+31.7% | 13.68+14.3% | 11.97+10781.8% | 0.11-99.9% | 148.98-0.3% | 149.40 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 196.79+57.1% | 125.23-15.7% | 148.54-18.2% | 181.64+29.7% | 140.08+250.6% | 39.95 | -0.11 | -118.60 | -84.77 |
| Total Shareholders Equity | 196.79+57.1% | 125.23-15.7% | 148.54-18.2% | 181.64+29.7% | 140.08+250.6% | 39.95 | -0.11 | -118.60 | -84.77 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 196.79+57.1% | 125.23-15.7% | 148.54-18.2% | 181.64+29.7% | 140.08+250.6% | 39.95 | -0.11 | -118.60 | -84.77 |
| Total Liabilities & Stockholders Equity | 222.15+58.2% | 140.40-10.5% | 156.88-21.4% | 199.65+29.8% | 153.76+196.2% | 51.91 | 0.00-100.0% | 30.38-53.0% | 64.62 |
| Book Value Per Share per share | 1.10+20.9% | 0.91-21.6% | 1.16-19.4% | 1.44+3.6% | 1.39+80.5% | 0.77 | -0.02 | -2.28 | -1.63 |
| Tangible Book Value Per Share per share | 1.10+20.9% | 0.91-21.6% | 1.16-19.4% | 1.44+3.6% | 1.39+80.5% | 0.77 | -0.02 | -2.28 | -1.63 |
| Full-Time Employees people | 39+11.4% | 35+9.4% | 32+23.1% | 26+8.3% | 24-22.6% | 31 | - | - | - |
| Price to Book Ratio ratio | 1.04 | 1.44 | 1.24 | 4.38 | 2.28 | 7.76 | - | - | - |
| Return on Assets % | -36.68 | -33.22 | -23.84 | -22.20 | -79.92 | -71.70 | -0.12 | -73.14 | - |
| Return on Equity % | -41.29 | -36.07 | -25.74 | -24.38 | -91.30 | - | - | - | - |
| Return on Invested Capital % | -32.34 | -37.54 | -28.51 | -21.38 | -57.42 | -70.55 | - | -168.99 | -68.17 |
| Quick Ratio ratio | 15.02 | 14.96 | 19.73 | 12.05 | 13.84 | 4.97 | 0.03 | 2.67 | 6.96 |
| Current Ratio ratio | 15.02 | 14.96 | 19.73 | 12.05 | 13.84 | 4.97 | 0.03 | 2.67 | 6.96 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY3/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -86.36 | -66.49 | -49.38 | -42.49 | -39.23 | -82.18 | -29.50 | -0.04 | -34.74 |
| Depreciation | 1.50 | 1.47-16.0% | 1.75-7.4% | 1.89-0.5% | 1.90+17.3% | 1.62-32.5% | 2.40 | - | 2.12 |
| Other Funds (Non Cash) | 14.21 | 6.70-3.0% | 6.91+139.1% | 2.89-35.2% | 4.46-91.8% | 54.65+1006.3% | 4.94 | 0.00 | 1.14 |
| Funds from Operations | -70.65 | -58.32 | -40.71 | -37.71 | -32.86 | -25.91 | -22.15 | -0.04 | -31.48 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 9.07 | 9.18 | -4.14 | -2.91 | -1.26-120.2% | 6.25 | -4.65-46600.0% | 0.01 | -0.26 |
| Cash from Operating Activities | -61.58 | -49.14 | -44.85 | -40.62 | -34.12 | -19.67 | -26.80 | -0.03 | -31.74 |
| Capital Expenditures | -0.36 | -0.03 | -0.04 | -0.03 | -0.21 | -1.89 | -0.11 | 0.00 | -0.47 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.18+50.0% | 0.12-14.3% | 0.14 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 52.77 | -93.28-299.2% | 46.82+73.4% | 27.00 | -151.16 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | -118.45 | -194.56 | -88.16 | -155.42 | -200.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 171.22 | 101.28-25.0% | 134.97-26.0% | 182.41+272.6% | 48.95 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 52.41 | -93.31-299.5% | 46.77+73.5% | 26.96 | -151.20 | -1.77-4525.0% | 0.04 | 0.00 | -0.47 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 5.13 | 130.64+643.5% | 17.57+468.6% | 3.09-95.9% | 75.76-40.8% | 127.99+136.3% | 54.16 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 5.13 | 130.64+643.5% | 17.57+468.6% | 3.09-95.9% | 75.76-40.8% | 127.99+136.3% | 54.16 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 3.85 | 129.36+636.3% | 17.57+479.9% | 3.03-96.0% | 75.74-40.8% | 127.99+136.3% | 54.16 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.38 | -5.62-18833.3% | 0.03 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.38 | -5.62 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.38 | -5.62 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.70 | -1.03 | -0.23 | -0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | -0.70 | -1.03 | -0.23 | -0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 4.43 | 129.61+647.5% | 17.34+489.8% | 2.94-96.1% | 75.76-36.1% | 118.61+144.4% | 48.54+161700.0% | 0.03 | 0.00 |
| Net Change in Cash | -4.74 | -12.84-166.7% | 19.25 | -10.72 | -109.57-212.8% | 97.17+346.3% | 21.77 | -0.00 | -32.21 |
| Free Cash Flow | -61.94 | -49.17 | -44.90 | -40.65 | -34.34 | -21.55 | -26.91 | -0.03 | -32.21 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 163.06-25.8% | 179.88+78.2% | 194.69+72.8% | 208.91+64.9% | 219.90+62.4% | 100.95-31.0% | 112.64-27.9% | 126.72-16.9% |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 2.44+98.4% | 1.01-80.8% | 1.00-91.3% | 0.91-84.9% | 1.23-78.6% | 5.25-28.3% | 11.51+387.7% | 6.03+324.6% |
| Total Current Assets | 165.50-25.2% | 180.89+70.3% | 195.69+57.6% | 209.82+58.1% | 221.12+56.7% | 106.19-30.8% | 124.14-21.7% | 132.75-13.7% |
| Net Property, Plant & Equipment | 8.43-11.9% | 8.71-12.4% | 8.91+32.2% | 9.20+29.9% | 9.57+28.6% | 9.94+468.0% | 6.74+205.0% | 7.08+165.2% |
| Total Investments and Advances | 0.570.0% | 0.570.0% | 0.570.0% | 0.57 | 0.57 | 0.57 | 0.57 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Deferred Tax Assets | - | - | - | 2.56 | - | - | - | - |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.57+78.1% |
| Total Assets | 174.50-24.5% | 190.17+63.0% | 205.17+56.1% | 222.15+58.2% | 231.26+55.1% | 116.70-25.0% | 131.45-18.4% | 140.40-10.5% |
| Short Term Debt Incl. Current Port. of LT Debt | 1.67+165.1% | 1.64+507.4% | 1.37+1145.5% | 1.00+194.1% | 0.63+12.5% | 0.27-75.2% | 0.11-91.0% | 0.34-71.7% |
| Accounts Payable | 6.32+103.9% | 2.91+11.9% | 0.91-42.4% | 1.58-29.8% | 3.10+222.9% | 2.60+118.5% | 1.58+85.9% | 2.25-45.0% |
| Other Current Liabilities | 16.38+88.7% | 11.59+5.5% | 8.00-39.4% | 11.38+80.9% | 8.68+197.3% | 10.99+52.0% | 13.21+629.8% | 6.29+150.6% |
| Total Current Liabilities | 24.37+96.4% | 16.13+16.4% | 10.28-31.0% | 13.97+57.5% | 12.41+180.1% | 13.86+45.7% | 14.90+283.0% | 8.87+13.7% |
| Long Term Debt | 7.56-18.1% | 8.00-16.9% | 8.42+34.3% | 8.83+40.2% | 9.23+46.0% | 9.63 | 6.27+3200.0% | 6.30+1066.7% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | 2.56 | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 31.93+47.5% | 24.12+2.7% | 18.70-11.7% | 25.36+67.2% | 21.65+101.4% | 23.49+147.0% | 21.17+418.9% | 15.17+81.9% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 142.57-32.0% | 166.05+78.1% | 186.47+69.1% | 196.79+57.1% | 209.61+51.5% | 93.21-36.2% | 110.28-29.8% | 125.23-15.7% |
| Total Shareholders Equity | 142.57-32.0% | 166.05+78.1% | 186.47+69.1% | 196.79+57.1% | 209.61+51.5% | 93.21-36.2% | 110.28-29.8% | 125.23-15.7% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 142.57-32.0% | 166.05+78.1% | 186.47+69.1% | 196.79+57.1% | 209.61+51.5% | 93.21-36.2% | 110.28-29.8% | 125.23-15.7% |
| Total Liabilities & Stockholders Equity | 174.50-24.5% | 190.17+63.0% | 205.17+56.1% | 222.15+58.2% | 231.26+55.1% | 116.70-25.0% | 131.45-18.4% | 140.40-10.5% |
| Book Value Per Share per share | 0.79-33.1% | 0.92+37.3% | 1.04+30.0% | 1.10+20.9% | 1.18+16.8% | 0.67-36.8% | 0.80-29.8% | 0.91-21.6% |
| Tangible Book Value Per Share per share | 0.79-33.1% | 0.92+37.3% | 1.04+30.0% | 1.10+20.9% | 1.18+16.8% | 0.67-36.8% | 0.80-29.8% | 0.91-21.6% |
| Full-Time Employees people | - | - | - | 39+11.4% | - | - | - | 35+9.4% |
| Price to Book Ratio ratio | 1.04 | 2.12 | 4.79 | 4.55 | 5.19 | 3.26 | 2.09 | 1.44 |
| Return on Assets % | -42.57 | -47.87 | -40.50 | -36.68 | -34.60 | -45.55 | -37.74 | -33.22 |
| Return on Equity % | -49.04 | -56.66 | -45.95 | -41.29 | -37.82 | -51.84 | -41.31 | -36.07 |
| Return on Invested Capital % | -18.10 | -14.45 | -9.40 | -7.64 | -6.52 | -19.33 | -14.27 | -11.43 |
| Quick Ratio ratio | 6.79 | 11.22 | 19.04 | 15.02 | 17.82 | 7.66 | 8.33 | 14.96 |
| Current Ratio ratio | 6.79 | 11.22 | 19.04 | 15.02 | 17.82 | 7.66 | 8.33 | 14.96 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -27.17 | -25.15 | -18.32 | -15.72 | -14.26 | -19.88 | -16.63 | -15.03 |
| Depreciation | 0.39+5.4% | 0.38+2.7% | 0.37+2.8% | 0.37+2.8% | 0.37-21.3% | 0.37-21.3% | 0.36-21.7% | 0.36-23.4% |
| Other Funds (Non Cash) | 4.09+375.6% | 4.62+73.7% | 4.87+91.7% | 0.63-68.0% | 0.86-55.2% | 2.66+91.4% | 2.54+55.8% | 1.97+149.4% |
| Funds from Operations | -22.69 | -20.15 | -13.08 | -14.72 | -13.03 | -16.85 | -13.73 | -12.71 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 6.38+192.7% | 5.42+8.0% | -4.19-905.8% | 1.46-58.8% | 2.18 | 5.02+991.3% | 0.52 | 3.54 |
| Cash from Operating Activities | -16.32 | -14.74 | -17.27 | -13.25 | -10.85 | -11.83 | -13.21 | -9.16 |
| Capital Expenditures | -0.11 | -0.18 | -0.08 | 0.00 | -0.01 | 0.00 | -0.02 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 22.44 | -4.80 | 38.51+231.7% | -3.38-122.0% | -95.15-427.4% | -6.36-198.1% | 11.61 | 15.37+143.2% |
| Purchase of Investments | -5.54 | -40.62 | -44.81 | -27.48 | -109.08 | -33.17 | -24.83 | -9.86 |
| Sale Or Maturity of Investments | 27.98+100.9% | 35.81+33.6% | 83.33+128.7% | 24.10-4.5% | 13.93-59.5% | 26.81-28.6% | 36.44-3.5% | 25.23-50.9% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 22.33 | -4.98 | 38.43+231.6% | -3.38-122.0% | -95.16-427.9% | -6.36-198.1% | 11.59 | 15.37+143.6% |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00-100.0% | 0.00 | 3.85 | 1.27 | 129.36 | 0.00 | 0.00-100.0% | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00-100.0% | 0.00 | 3.85 | 1.27 | 129.36 | 0.00 | 0.00-100.0% | 0.00 |
| Proceedsfrom Stock Options | 0.00-100.0% | 0.00 | 3.85 | 0.00 | 129.36 | 0.00 | 0.00-100.0% | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | -0.49 | -0.21 | 0.00 | 0.00 | -0.81 | -0.10 |
| Other Financing Activities Uses | 0.00 | 0.00 | -0.49 | -0.21 | 0.00 | 0.00 | -0.81 | -0.10 |
| Cash from Financing Activities | 0.00-100.0% | 0.00 | 3.37 | 1.06 | 129.36 | 0.00 | -0.81-104.6% | -0.09 |
| Net Change in Cash | 6.02-74.2% | -19.71 | 24.52 | -15.57-354.8% | 23.36+30.1% | -18.19 | -2.44 | 6.11 |
| Free Cash Flow | -16.42 | -14.91 | -17.35 | -13.25 | -10.86 | -11.83 | -13.23 | -9.16 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2024 share |
|---|---|---|
| Biological Products, (No Diagnostic Substances) | 0.85 | 100.0% |
| Total | 0.85 | 100.0% |
| Name | 2024 | 2024 share |
|---|---|---|
| United States | 0.85 | 100.0% |
| Total | 0.85 | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 31.68% | 40.8M | 128.7M | 4.25M |
| 2026-10-15 | 32.50% | 41.8M | 128.7M | 4.26M |
| 2026-09-30 | 29.56% | 40.4M | 136.5M | 3.41M |
| 2026-09-15 | 30.50% | 41.6M | 136.6M | 2.99M |
| 2026-08-31 | 29.87% | 40.8M | 136.6M | 3.13M |
| 2026-08-14 | 29.43% | 40.2M | 136.6M | 3.57M |
| 2026-07-31 | 31.13% | 39.9M | 128.1M | 4.19M |
| 2026-07-15 | 30.68% | 39.3M | 128.1M | 8.00M |
| 2026-06-30 | 28.99% | 37.1M | 128.1M | 7.98M |
| 2026-06-15 | 25.38% | 32.5M | 128.1M | 7.55M |
| 2026-05-29 | 25.97% | 33.3M | 128.1M | 7.38M |
| 2026-05-15 | 25.12% | 31.0M | 123.5M | 6.93M |
| 2026-04-30 | 25.17% | 30.4M | 120.9M | 6.00M |
| 2026-04-15 | 21.60% | 26.1M | 120.7M | 2.21M |
| 2026-03-31 | 20.70% | 26.1M | 126.2M | 2.25M |
| 2026-03-13 | 18.87% | 23.8M | 126.2M | 2.20M |
| 2026-02-27 | 18.23% | 23.0M | 126.2M | 2.14M |
| 2026-02-13 | 17.94% | 22.4M | 124.6M | 2.16M |
| 2026-01-30 | 17.72% | 21.9M | 123.8M | 2.20M |
| 2026-01-15 | 18.58% | 23.0M | 123.8M | 2.12M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 0.50 | 0.05 | 0.55 | 0.44 | - | 4.00 | 0.00 | 0.863 | -0.007 | 0.000 |
| call | 1.00 | 0.00 | 0.05 | 0.02 | - | 4,566 | 5,203 | 0.332 | -0.006 | 0.000 |
| call | 1.50 | 0.00 | 0.25 | 0.05 | - | 278 | 0.00 | 0.231 | -0.009 | 0.000 |
| call | 2.00 | 0.00 | 0.05 | 0.01 | - | 6,345 | 1.00 | 0.201 | -0.011 | 0.000 |
| call | 3.00 | 0.00 | 0.05 | 0.02 | - | 23,661 | 0.00 | 0.175 | -0.011 | 0.000 |
| call | 4.00 | 0.00 | 0.05 | 0.04 | - | 112 | 0.00 | 0.163 | -0.012 | 0.000 |
| call | 5.00 | 0.00 | 0.05 | 0.05 | - | 3,789 | 0.00 | 0.157 | -0.014 | 0.000 |
| call | 6.00 | 0.00 | 0.05 | 0.21 | - | 20.00 | 0.00 | 0.151 | -0.013 | 0.000 |
| call | 7.00 | 0.00 | 0.50 | 0.05 | - | 4.00 | 0.00 | 0.150 | -0.015 | 0.000 |
| call | 8.00 | 0.00 | 0.75 | 0.27 | - | 8.00 | 0.00 | 0.145 | -0.016 | 0.000 |
| call | 9.00 | 0.00 | 0.75 | 0.00 | - | 0.00 | 0.00 | 0.142 | -0.016 | 0.000 |
| call | 10.00 | 0.00 | 1.25 | 0.00 | - | 0.00 | 0.00 | 0.140 | -0.016 | 0.000 |
| call | 11.00 | 0.00 | 1.50 | 0.20 | - | 1.00 | 0.00 | 0.139 | -0.017 | 0.000 |
| call | 12.00 | 0.00 | 1.25 | 0.00 | - | 0.00 | 0.00 | 0.137 | -0.017 | 0.000 |
| call | 13.00 | 0.00 | 0.95 | 0.00 | - | 0.00 | 0.00 | 0.136 | -0.017 | 0.000 |
| put | 0.50 | 0.00 | 0.20 | 0.03 | - | 0.00 | 0.00 | -0.137 | -0.007 | 0.000 |
| put | 1.00 | 0.10 | 0.25 | 0.20 | - | 1,236 | 0.00 | -0.668 | -0.006 | 0.000 |
| put | 1.50 | 0.30 | 1.05 | 0.80 | - | 141 | 0.00 | -0.769 | -0.009 | 0.000 |
| put | 2.00 | 0.95 | 1.40 | 1.22 | - | 90.00 | 0.00 | -0.799 | -0.011 | 0.000 |
| put | 3.00 | 1.80 | 2.55 | 2.17 | - | 2.00 | 0.00 | -0.824 | -0.012 | 0.000 |
| put | 4.00 | 2.60 | 3.80 | 3.26 | - | 0.00 | 0.00 | -0.836 | -0.013 | 0.000 |
| put | 5.00 | 3.60 | 4.80 | 4.14 | - | 0.00 | 0.00 | -0.843 | -0.014 | 0.000 |
| put | 6.00 | 4.60 | 5.80 | 5.32 | - | 2.00 | 0.00 | -0.848 | -0.014 | 0.000 |
| put | 7.00 | 5.40 | 6.90 | 6.14 | - | 0.00 | 0.00 | -0.852 | -0.015 | 0.000 |
| put | 8.00 | 6.40 | 7.90 | 7.25 | - | 0.00 | 0.00 | -0.855 | -0.015 | 0.000 |
| put | 9.00 | 7.40 | 8.90 | 8.25 | - | 1.00 | 0.00 | -0.858 | -0.015 | 0.000 |
| put | 10.00 | 8.40 | 9.90 | 9.30 | - | 1.00 | 0.00 | -0.860 | -0.015 | 0.000 |
| put | 11.00 | 9.40 | 10.90 | 10.25 | - | 2.00 | 0.00 | -0.861 | -0.015 | 0.000 |
| put | 12.00 | 10.40 | 11.90 | 11.25 | - | 0.00 | 0.00 | -0.863 | -0.016 | 0.000 |
| put | 13.00 | 11.00 | 13.40 | 12.27 | - | 1.00 | 0.00 | -0.864 | -0.016 | 0.000 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | SCHEDULE 13G | SEC | ||
| 2026-11-09 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-09 | 8-K | Current report | 2026-11-09 | SEC |
| 2026-10-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-01 | SEC |
| 2026-09-25 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-24 | SEC |
| 2026-09-22 | 8-K | Current report | 2026-09-22 | SEC |
| 2026-08-14 | SCHEDULE 13G/A | SEC | ||
| 2026-08-07 | SCHEDULE 13G | SEC | ||
| 2026-08-06 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-06 | 8-K | Current report | 2026-08-06 | SEC |
| 2026-07-01 | 8-K | Current report | 2026-07-01 | SEC |
| 2026-06-23 | 8-K | Current report | 2026-06-22 | SEC |
| 2026-06-11 | 8-K | Current report | 2026-06-10 | SEC |
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-05-05 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-05 | 8-K | Current report | 2026-05-05 | SEC |
| 2026-04-30 | 4/A | 2026-04-29 | SEC | |
| 2026-04-30 | 4/A | 2026-04-29 | SEC | |
| 2026-04-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-04-29 | SEC |
| 2026-04-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-04-29 | SEC |
| 2026-04-29 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
| 2026-04-29 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-04-29 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-06-10 | SEC |
| 2026-04-27 | 8-K | Current report | 2026-04-27 | SEC |
| 2026-03-12 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-03-05 | 10-K | Annual report pursuant to Section 13 or 15(d) | 2025-12-31 | SEC |
| 2026-03-05 | 8-K | Current report | 2026-03-05 | SEC |
| 2026-02-13 | SCHEDULE 13G/A | SEC | ||
| 2026-02-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-02-08 | SEC |
| 2026-01-21 | SCHEDULE 13G | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 18.40K | 1 | 0 | 0 |
| 2026-09 | 2.85K | 1 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| TANG CAPITAL MANAGEMENT LLC | 9.99% |
| ORBIMED ADVISORS LLC | 8.45% |
| MONTANOVA CAPITAL, LLC | 7.83% |
| BlackRock, Inc. | 6.26% |
| Enavate Sciences GP, LLC | 4.32% |
| Vivo Capital, LLC | 4.31% |
| STATE STREET CORP | 4.30% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.40% |
| Palo Alto Investors LP | 3.24% |
| MILLENNIUM MANAGEMENT LLC | 2.62% |
Funds
| Fund | % owned |
|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3.80% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.33% |
| iShares Russell 2000 ETF | 1.92% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.00% |
| Fidelity Small Cap Index Fund | 0.79% |
| iShares Russell 2000 Value ETF | 0.67% |
| Fidelity Enhanced Small Cap Core ETF | 0.62% |
| VANGUARD EXPLORER FUND | 0.53% |
| Fidelity Extended Market Index Fund | 0.46% |
| SMALL COMPANY GROWTH PORTFOLIO | 0.43% |
OakChart. CMPX. Cached 15 minutes. Terms